IsoPlexis Corp

IsoPlexis — IPO Roadshow (January 2022)

30 slides from IsoPlexis's IPO roadshow presentation, Jan 10, 2022

  1. Slide 1: The Superhuman Cell Company

    088 ISOplexis The Superhuman Cell Company January 2021

  2. Slide 2: Disclaimer and Forward-Looking Statements

    Disclaimer and Forward-Looking Statements IsoPlexis Corporation (“IsoPlexis,” “we,” “us,” or the “Company”) has filed a prospectus on Form S-1 (File No. 333-258046) with the SEC for the offering to which this presentation relates. The registration statement has not yet become effective. Before you i

  3. Slide 3: We Leverage the Superhuman Cells in All of Us

    WE LEVERAGE THE SUPERHUMAN CELLS IN ALL OF US TO CHANGE THE COURSE OF HUMAN HEALTH

  4. Slide 4: Large opportunity to change the course of human health

    4 209 instruments in the field1 64-66% YTD revenue growth through Q4 20213 98 Publications leveraging superhuman cells to fight complex diseasesLarge opportunity to change the course of human health as The Superhuman Cell Company Platform impact encompasses 3 sequential TAMs totaling $34B 2 1 As of

  5. Slide 5: Three Disconnected Paradigms Changing Biology & Medicine

    Three Disconnected Paradigms Changing Biology & Medicine 5 FUNCTIONAL PROTEOMICS SINGLE-CELL BIOLOGY SINGLE-CELL MULTI-OMICS GAP GAP Captures dynamic in vivo biology Captures important yet rare cells Captures genetic code underlying important cells

  6. Slide 6: IsoPlexis' Superhero Cells Connect These Three Paradigms

    IsoPlexis’ Superhero Cells Connect These Three Paradigms 6 FUNCTIONAL PROTEOMICS SINGLE-CELL BIOLOGY DUOMIC™ PLATFORM + + Proteomically active single cells are the superhero cells that orchestrate the fight against disease

  7. Slide 7: Why Proteome is Critical to Superhero Cells

    Why Proteome is Critical to Superhero Cells 7 TRANSCRIPTOME PROTEOME Clinical activity in human health dictated by direct proteome activity Low correlation (0.4)* between transcription/RNA and proteomic cell function *Vogel et al. Nature Reviews Genetics, 2012 Single cell genomics misses key proteom

  8. Slide 8: IsoPlexis' Unique Superhero Cells are Key to Fighting Cancer

    IsoPlexis’ Unique Superhero Cells are Key to Fighting Cancer 8 IsoPlexis reveals highly proteomically “multi-functional” superhero immune cells Presence of these cells are key predictors of early and persistent response to cancer * High Frequency of Superhero Cells * Representative of high impact pu

  9. Slide 9: Superhero cells are advancing the fight against many critical diseases

    Superhero cells are advancing the fight against many critical diseases 9 Superhero and supervillain cells play key predictive role CELL THERAPY CANCER IMMUNOLOGY COVID-19 TARGETED THERAPIES INFLAMMATION

  10. Slide 10: Revealing superhero cells in the proteomics landscape

    Revealing superhero cells in the proteomics landscape Cell type (Flow cytometry and single cell genomics) vs IsoPlexis’ superhero cell function 10 Surface markers (flow cytometry and single cell genomics) hides true identity Multiplexed cytokines reveal the unique power of the individual super cell

  11. Slide 11: Wave of Bulk Proteomics Drives Need for Single Cell Proteomics

    Wave of Bulk Proteomics Drives Need for Single Cell Proteomics 11 BULK PROTEOMICS Discover important protein analytes driving disease and patient response Reveal the cells producing proteomic reactions, the earliest signals orchestrating patient response SINGLE CELL PROTEOMICS Not Single Cell REVEAL

  12. Slide 12: Critical, Unique Use Cases Supported In Many High Impact Journals

    Critical, Unique Use Cases Supported In Many High Impact Journals 12 Superhero cells make the best products for clinical response Superhero cells show which patients respond durably to cancer therapies Supervillain cells show which patients go to ICU with autoimmune response Cell and Gene Therapy Ca

  13. Slide 13: Single Cell Proteomics Rapidly Establishing Advanced Medicine Leadership

    Single Cell Proteomics Rapidly Establishing Advanced Medicine Leadership 13 98 PUBLICATIONS 67% OF COMPREHENSIVE CANCER CENTERS2 100% OF TOP 15 PHARMA1 1 By 2020 revenue. 2 Based on the National Cancer Institute’s list of Comprehensive Cancer Centers.

  14. Slide 14: Superhero Cell Biology Drives Large Advanced Medicine Opportunity

    Superhero Cell Biology Drives Large Advanced Medicine Opportunity 141 Consulting research. 2 Based on management estimates 0 500 1,000 1,500 2,000 2,500 3,000 3,500 Pre-clinical Phase 1 Phase 2 Phase 3 Gene therapies Cell therapies Small molecules Vaccines Proteins and antibodies ~5.5K APPLICABLE TH

  15. Slide 15: Create Large, High Need Markets

    DISCOVERY CLINICAL Duomic + Single Cell Proteome Single Cell Proteome (Dx) Unique and Large Impact on Human Health Create Large, High Need Markets 15 Genomics ”Cell Atlas” Bulk Proteomics + + = Mid-Term Today Long-term 1 Based on management estimates.

  16. Slide 16: Accessible, Automated Proteomic Workflow is Key to Adoption & Usage

    Accessible, Automated Proteomic Workflow is Key to Adoption & Usage 16 Cryopreserved Samples SAMPLES: MANY CELL TYPES AND PROTOCOLS CUMULATIVE INSTRUMENTS IN THE FIELD1 INSTRUMENT: AUTOMATED FUNCTIONAL PROTEOMICS HUB AUTOMATED ANALYTIC SOFTWARE: ACCESSIBLE INSIGHTS 18 54 111 209 2018 2019 2020 2021

  17. Slide 17: The Superhuman Cell Library

    The Superhuman Cell Library: The Proteomic Complement To The Genomic Cell Atlas 17 Supercharged Immunology SUPERHERO CELLS Hyper Inflammation SUPERVILLAIN CELLS Aberrant Malignancies SUPERVILLAIN CELLS Key categories you can explore A New Library of Proteomically Active Cells to Fight all of Disease

  18. Slide 18: Proprietary Single-Cell Proteomic Barcoding Platform

    Proprietary Single-Cell Proteomic Barcoding Platform: Powerful Biology 18 30+ Proteins Per Cell1. Sample Loaded onto Chip 3. Highly Multiplexed Proteomic Detection2. Single Cell Capture Single Cell Proteomics Larger “Superhuman Cell Library” + Panels = Comprehensiveness Leveraging Duomic for first C

  19. Slide 19: CAR-T Engineering Unlocked with Single Cell Proteomics

    CAR-T Engineering Unlocked with Single Cell Proteomics 19Source: 1Spiegel et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021 Development Question from Leaders at Stanford: What are we miss

  20. Slide 20: Predictive Durability of SC Proteomics is Accelerating Cancer Immunology

    Predictive Durability of SC Proteomics is Accelerating Cancer Immunology 20Source: Diab et al. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. Journal of Clinical Oncology. 2021. PREDICTS LONG TERM THERAPY RESPONSE Predicting Survival in Cancer Immunology: In a 38 patient metasta

  21. Slide 21: Duomic: Sequencing The Superhero Cells For A New Era Of Discovery

    Duomic: Sequencing The Superhero Cells For A New Era Of Discovery 21 Hypothesis-free discovery with high plex on dissociated cells Fill in the Missing Multi-Omic Gaps Utilize Predictive Single cell proteomics to drive long term response in the clinic Increasing Specificity of Hypothesis on Cell Func

  22. Slide 22: Single Cell Is Evolving To Leverage Clinically Relevant Proteome

    Single Cell Is Evolving To Leverage Clinically Relevant Proteome 22 PAST AND PRESENT Cell Type Identification Through SC –Omics Single-Cell Uni -Omics • SC RNA-seq • SC ATAC-seq Single-Cell Multi -Omics • SC RNA seq + surface proteomics • SC RNA-seq + ATAC-seq PRESENT AND IMMINENT Cell Functional El

  23. Slide 23: Duomic: How We Capture The Genetic Drivers of Superhero Cells

    Duomic: How We Capture The Genetic Drivers of Superhero Cells 23 LEVERAGE CORE SINGLE-CELL PLATFORM PROTEOME DETECTED AND TRANSCRIPTOME CAPTURED SEQUENCE DETECTED PROTEIN + SEQUENCING LINKED, PER CELL Capture Chambers Unique Cellular Identifier Single-Cell Proteomic Barcode Chamber #250 Bead RNA Cap

  24. Slide 24: Sequencing The Supercells Provides Additional $12B Discovery TAM

    Sequencing The Supercells Provides Additional $12B Discovery TAM 241 Based on management estimates. 2 Consulting research / survey data. * Estimated sequencer base, consulting research A Functional “Multi-omic” system upstream of every sequencer 2 CRITICAL NEED TO LINK THE GENOME TO CLINICALLY RELEV

  25. Slide 25: An Integrated Roadmap & Large Opportunity

    Near-term Today $24B $12B 25 Single-Cell Multi-Omics Single-Cell Proteomics (Dx) 1 Based on management estimates. Execute Technology & Clinical Publication Focused Roadmap An Integrated Roadmap & Large Opportunity $34B Single-Cell Proteomics

  26. Slide 26: Foundational Patents Issued and Filed Underpins Continued Expansion

    153 Foundational Patents Issued and Filed Underpins Continued Expansion 26 • Bulk Proteomic Barcoding • Small Volume Serum Analysis • Secretomic Capture • Intracellular Proteome Capture • Metabolomic Capture IsoSpark IsoSpeak • Automated Instrumentation and Software • Single-Cell and High Multiplex

  27. Slide 27: Seasoned Management Built to Scale

    LEADERSHIP BUILT TO SCALE: Continued additions to global leadership team from leading Life Science Tools companies – built to scale growth COMMERCIAL GROWTH: Team built around senior leadership with track record in genomic, proteomic, and other med tech applications GLOBAL FOCUS: Directors in major

  28. Slide 28: For Research Use Only. Not for Use in Diagnostic Procedures

    © 2021 ISOPLEXIS | ALL RIGHTS RESERVED For Research Use Only. Not for Use in Diagnostic Procedures.

  29. Slide 29: Appendix 1: Superhero Cells In Leading Clinical Journals

    Appendix 1: Superhero Cells In Leading Clinical Journals On Unique Single-Cell Proteomics 29 Our results suggest that engineering iterations should be guided by careful studies of single-cell CAR polyfunctionality incorporating cytokine production as a critical quality attribute - Nature Medicine, J

  30. Slide 30: Appendix 2: Revealing the Genetic Drivers of Potentially Resistant Tumor Cells

    Appendix 2: Revealing the Genetic Drivers of Potentially Resistant Tumor Cells First of its kind Duomic data presented at AGBT 30*All displayed genes had differential expression between the two cell subsets (p value < 0.05) High protein/gene expression intensity Low protein/gene expression intensity

IsoPlexis — IPO Roadshow (January 2022) on 6ix